Education
About Us
Working with TipRanks
Follow Us
Stayble Therapeutics AB (SE:STABL)
FRANKFURT:STABL
STABL Stock Chart & Stats
kr0.24
kr0.07(17.59%)
At close: 4:00 PM EST
kr0.24
kr0.07(17.59%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.70
Previous CloseN/A
Volume514.07K
Average Volume (3M)378.51K
Market Cap
kr13.58M
Enterprise Valuekr14.42M
Total Cash (Recent Filing)kr3.80M
Total Debt (Recent Filing)kr850.00K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding64,359,795
10 Day Avg. Volume398,578
30 Day Avg. Volume378,512
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STABL FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was kr0.15 and its highest was kr0.70 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is kr13.58M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
Stayble Therapeutics AB’s upcoming earnings report date is Feb 25, 2026 which is in 61 days.
How were Stayble Therapeutics AB’s earnings last quarter?
Stayble Therapeutics AB released its earnings results on Nov 19, 2025. The company reported -kr0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.023.
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Stayble Therapeutics AB reported an EPS of -kr0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.548%.
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in SE:STABL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.
Technical Analysis
Diagonal Bio AB
―
LIDDS AB
―
CombiGene AB
―
Fluicell AB
―
QuiaPEG Pharmaceuticals Holding AB
―